Exelixis Q3 Revenue Jumps 10% to $658.7M, Tax Guidance Cut, New Zanzalintinib Readout Set for Q1 2027
EXEL sits 84% above its 52-week low of $36.
Summary
Exelixis beat its own prior-year pace with Q3 total revenues of $658.7 million versus $597.8 million, driven by net product revenues of $604.9 million from the cabozantinib franchise. GAAP net income came in at $218.1 million, or $0.85 per diluted share, and non-GAAP net income was $240.2 million, or $0.94 per diluted share. Full-year 2026 guidance for total revenues ($2.500-$2.550 billion) and net product revenues ($2.300-$2.350 billion) was unchanged, but the company cut its effective tax rate outlook to 16%-18% from 21%-23%, which lifts expected net income without any revenue change. The pipeline update adds a concrete date: topline results from the phase 3 STELLAR-304 trial in non-clear cell renal cell carcinoma are now expected in the first quarter of 2027, a fresh readout that did not previously have a stated timeframe. On the legal side, Exelixis signed a settlement and license agreement with Azurity on October 28 granting U.S. market entry for its proposed 505(b)(2) product on December 1, 2030, extending the generic cabozantinib runway. The company has repurchased $402.1 million under its May 2026 $750 million program at an average of $54.03 per share, with shares now near a 52-week high.
At the time of this announcement, EXEL was trading at $66.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4B. The 52-week trading range was $36.00 to $67.52. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.